These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 27405680)

  • 41. A critical appraisal of one-stage and chromogenic assays of factor VIII activity.
    Peyvandi F; Oldenburg J; Friedman KD
    J Thromb Haemost; 2016 Feb; 14(2):248-61. PubMed ID: 26663865
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays.
    Pavlova A; Delev D; Pezeshkpoor B; Müller J; Oldenburg J
    Thromb Haemost; 2014 May; 111(5):851-61. PubMed ID: 24452774
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monitoring of modified factor VIII and IX products.
    Kitchen S; Gray E; Mertens K
    Haemophilia; 2014 May; 20 Suppl 4():36-42. PubMed ID: 24762273
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chromogenic assays for equine coagulation factors VII, VIII:C, IX, and X, and C1-esterase inhibitor.
    Topper MJ; Prasse KW
    Am J Vet Res; 1998 May; 59(5):538-41. PubMed ID: 9582952
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B.
    Abraham S; Duncan EM
    Methods Mol Biol; 2023; 2663():569-588. PubMed ID: 37204737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A blinded in vitro study with Refacto mock plasma samples: similar FVIII results between the chromogenic assay and a one-stage assay when using a higher cephalin dilution.
    Caron C; Dautzenberg MD; Delahousse B; Droulle C; Pouzol P; Dubanchet A; Rothschild C
    Haemophilia; 2002 Sep; 8(5):639-43. PubMed ID: 12199672
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of Chromogenic Factor VIII Assay Compared with One-Stage Clotting Assay.
    Akkaya E; Hatiboglu S; Koc B; Genc S; Unuvar A; Karaman S; Omer B; Karakas Z; Zulfikar B
    Clin Lab; 2020 Oct; 66(10):. PubMed ID: 33073956
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Little discrepancy between one-stage and chromogenic factor VIII (FVIII)/IX assays in a large international cohort of persons with nonsevere hemophilia A and B.
    Zwagemaker AF; Kloosterman FR; Gouw SC; Boyce S; Brons P; Cnossen MH; Collins PW; Eikenboom J; Hay C; Hengeveld RCC; Jackson S; Klopper-Tol CAM; Kruip MJHA; Gorkom BL; Male C; Nieuwenhuizen L; Shapiro S; Fijnvandraat K; Coppens M;
    J Thromb Haemost; 2023 Apr; 21(4):850-861. PubMed ID: 36696222
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Collaborative study for the establishment of replacement batches for human coagulation factor IX concentrate reference standards.
    Gray E; Pickering W; Hockley J; Rigsby P; Weinstein M; Terao E; Buchheit KH
    Pharmeuropa Bio; 2008 Dec; 2008(1):19-30. PubMed ID: 19220978
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activity measurements of dalcinonacog alfa.
    Williams SC; Gray E
    Haemophilia; 2020 Mar; 26(2):346-353. PubMed ID: 32142203
    [TBL] [Abstract][Full Text] [Related]  

  • 51. One-Stage Factor VIII Assays.
    Duncan E; Rodgers S
    Methods Mol Biol; 2017; 1646():247-263. PubMed ID: 28804834
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates.
    Lundblad RL; Kingdon HS; Mann KG; White GC
    Thromb Haemost; 2000 Dec; 84(6):942-8. PubMed ID: 11154139
    [TBL] [Abstract][Full Text] [Related]  

  • 53. International comparative field study of N8 evaluating factor VIII assay performance.
    Viuff D; Barrowcliffe T; Saugstrup T; Ezban M; Lillicrap D
    Haemophilia; 2011 Jul; 17(4):695-702. PubMed ID: 21426445
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Factor VIII assay mimicking in vivo coagulation conditions.
    Kusch M; Grundmann C; Keitel S; König H
    Haemophilia; 2014 Mar; 20(2):e164-70. PubMed ID: 24286249
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Variability in factor VIII concentrate measurement: results from SSC field collaborative studies.
    Raut S; Sands D; Heath AB; Barrowcliffe TW
    J Thromb Haemost; 2003 Sep; 1(9):1927-34. PubMed ID: 12941033
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of chromogenic assays in haemophilia A and B diagnosis.
    Bowyer AE; Duncan EM; Antovic JP
    Haemophilia; 2018 Jul; 24(4):578-583. PubMed ID: 29808946
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chromogenic Factor VIII Assays for Improved Diagnosis of Hemophilia A.
    Rodgers S; Duncan E
    Methods Mol Biol; 2017; 1646():265-276. PubMed ID: 28804835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activation profiles of factor VIII in concentrates reflect one-stage/chromogenic potency discrepancies.
    Hubbard AR; Weller LJ; Bevan SA
    Br J Haematol; 2002 Jun; 117(4):957-60. PubMed ID: 12060137
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Measurement of B-domain-deleted ReFacto AF activity with a product-specific standard is affected by choice of reagent and patient-specific factors.
    Jacquemin M; Vodolazkaia A; Toelen J; Schoeters J; Van Horenbeeck I; Vanlinthout I; Debasse M; Peerlinck K
    Haemophilia; 2018 Jul; 24(4):675-682. PubMed ID: 28124445
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FIXing postinfusion monitoring: Assay experiences with N9-GP (nonacog beta pegol; Refixia
    Ezban M; Hermit MB; Persson E
    Haemophilia; 2019 Jan; 25(1):154-161. PubMed ID: 30664825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.